Association of adventitial vasa vasorum and inflammation with coronary hyperconstriction after drug-eluting stent implantation in pigs in vivo

Circulation Journal

Volumn 79, Issue 8, 2015, Pages 1787-1798

  Nishimiya, Kensuke ^a   Matsumoto, Yasuharu ^a   Shindo, Tomohiko ^a   Hanawa, Kenichiro ^a   Hasebe, Yuhi ^a   Tsuburaya, Ryuji ^a   Shiroto, Takashi ^a   Takahashi, Jun ^a   Ito, Kenta ^a   Ishibashi Ueda, Hatsue ^b   Yasuda, Satoshi ^b   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Adventitia; Rho kinase; Spasm; Stents; Vasoconstriction

Indexed keywords

HYDROXYFASUDIL; RHO KINASE; SEROTONIN; RAPAMYCIN;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY SPASM; DRUG ELUTING STENT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NONHUMAN; PIG; PROTEIN EXPRESSION; SIROLIMUS ELUTING STENT; VASA VASORUM; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; CORONARY VASOSPASM; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CORONARY VASOSPASM; DRUG-ELUTING STENTS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; RHO-ASSOCIATED KINASES; SIROLIMUS; SWINE; VASA VASORUM;

EID: 84937933613     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0149     Document Type: Article

References (38)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
2. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with baremetal stents. N Engl J Med 2007; 356: 989-997.
3. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008; 118: 1138-1145.
4. Takeda M, Shiba N, Takahashi J, Shimokawa H. A case report of very late stent thrombosis with peri-stent coronary artery aneurysm and stent-related coronary vasospasm. Cardiovasc Interv Ther 2013; 28: 272-278.
5. Aizawa K, Yasuda S, Takahashi J, Takii T, Kikuchi Y, Tsuburaya R, et al. Involvement of Rho-kinase activation in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in patients with coronary artery disease. Circ J 2012; 76: 2552-2560.
6. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46: 231-236.
7. Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008; 51: 2123-2129.
8. Shimokawa H. 2014 Williams Harvey Lecture: Importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart J 2014; 35: 3180-3193.
9. Garg S, Bourantas C, Serruys PW. New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol 2013; 10: 248-260.
10. Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C, et al. Polymer-free biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting Cypher stent in a porcine model. Circ Cardiovasc Interv 2010; 3: 174-183.
11. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, et al. Long-term clinical outcomes of biodegradable polymer biolimus- eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378: 1940-1948.
12. Pendyala LK, Matsumoto D, Shinke T, Iwasaki T, Sugimoto R, Hou D, et al. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with cypher stent. JACC Cardiovasc Interv 2012; 5: 436-444.
13. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Kawano Y, Fukata Y, et al. Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β. Circulation 2000; 101: 1319-1323.
14. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
15. Shiroto T, Yasuda S, Tsuburaya R, Ito Y, Takahashi J, Ito K, et al. Role of Rho-kinase in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in pigs in vivo. J Am Coll Cardiol 2009; 54: 2321-2329.
16. Tsuburaya R, Yasuda S, Shiroto T, Ito Y, Gao JY, Aizawa K, et al. Long-term treatment with nifedipine suppresses coronary hyperconstricting responses and inflammatory changes induced by paclitaxeleluting stent in pigs in vivo: Possible involvement of Rho-kinase pathway. Eur Heart J 2012; 33: 791-799.
17. Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, et al. Chronic treatment with interleukin-1β induces coronary intimal lesions and vasospastic responses in pigs in vivo: The role of platelet-derived growth factor. J Clin Invest 1996; 97: 769-776.
18. Maiellaro K, Taylor WR. The role of the adventitia in vascular inflammation. Cardiovasc Res 2007; 75: 640-648.
19. Wilson SH, Herrmann J, Lerman LO, Holmes DR Jr, Napoli C, Ritman EL, et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002; 105: 415-418.
20. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-2325.
21. Drinane M, Mollmark J, Zagorchev L, Moodie K, Sun B, Hall A, et al. The antiangiogenic activity of rPAI-123 inhibits vasa vasorum and growth of atherosclerotic plaque. Circ Res 2009; 104: 337-345.
22. Tanaka K, Nagata D, Hirata Y, Tabata Y, Nagai R, Sata M. Augmented angiogenesis in adventitia promotes growth of atherosclerotic plaque in apolipoprotein E-deficient mice. Atherosclerosis 2011; 215: 366-373.
23. Kwon HM, Sangiorgi G, Ritman EL, Lerman A, McKenna C, Virmani R, et al. Adventitial vasa vasorum in balloon-injured coronary arteries: Visualization and quantitation by a microscopic threedimensional computed tomography technique. J Am Coll Cardiol 1998; 32: 2072-2079.
24. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, et al. Drug-eluting stents in preclinical studies: Recommended evaluation from a consensus group. Circulation 2002; 106: 1867-1873.
25. Hirata Y, Tabata M, Kurobe H, Motoki T, Akaike M, Nishio C, et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol 2011; 58: 248-255.
26. Maseri A, Beltrame JF, Shimokawa H. Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic targets. Circ J 2009; 73: 394-403.
27. Virmani R, Kolodie FD, Farb A, Lafont A. Drug-eluting stents: Are human and animal studies comparable? Heart 2003; 89: 133-138.
28. Miyata K, Shimokawa H, Kandabashi T, Higo T, Morishige K, Eto Y, et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 2000; 20: 2351-2358.
29. Sahler LG, Davis D, Saad WE, Patel NC, Lee DE, Waldman DL. Comparison of vasa vasorum after intravascular stent placement with sirolimis drug-eluting and bare metal stents. J Med Imaging Radiat Oncol 2008; 52: 570-575.
30. Herrmann J, Lerman LO, Rodriguez-Porcel M, Holmes DR Jr, Richardson DM, Ritman EL, et al. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res 2001; 51: 762-766.
31. Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ II, Virmani R. Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 1985; 313: 1138-1141.
32. Campbell KA, Lipinski MJ, Doran AC, Skaflen MD, Fuster V, McNamara CA. Lymphocytes and the adventitial immune response in atherosclerosis. Circ Res 2012; 110: 889-900.
33. Nihei T, Takahashi J, Tsuburaya R, Ito Y, Takagi Y, Matsumoto Y, et al. Circadian variation of Rho-kinase activity in circulating leukocytes of patients with vasospastic angina. Circ J 2014; 78: 1183-1190.
34. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004; 63: 617-624.
35. Hiranuma N, Shinke T, Kakazawa G, Otake H, Matsumoto D, Ijichi T, et al. Optial coherence tomography and histopathplogy assessment after implantation of first- and second-generation drug-eluting stents in a procine coronary model. Circ J 2014; 78: 2665-2673.
36. Graser T, Leisner H, Tiedt N. Absence of role of endothelium in the response of isolated porcine coronary arteries to acetylcholine. Cardiovasc Res 1986; 20: 299-302.
37. Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Odaka Y, Nihei T, et al. In vivo visualization of adventitial vasa vasorum of the human coronary artery on optical frequency domain imaging: Validation study. Circ J 2014; 78: 2516-2518.
38. Nishimiya K, Matsumoto Y, Uzuka H, Oyama K, Tanaka A, Taruya A, et al. Accuracy of optical frequency domain imaging for evaluation of coronary adventitial vasa vasorum formation after stent implantation in pigs and humans: A validation study. Circ J 2015; 79: 1323-1331.